Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China.
The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China.
Nanotechnology. 2024 Sep 6;35(47). doi: 10.1088/1361-6528/ad7034.
Inflammation involving adipose macrophages is an important inducer of obesity. Regulating macrophages polarization and improving the inflammatory microenvironment of adipose tissue is a new strategy for the treatment of obesity. An amphiphilic chondroitin sulfate phenylborate derivative (CS-PBE) was obtained by modifying the main chain of chondroitin sulfate with the hydrophobic small molecule phenylborate. Using CS-PBE self-assembly, macrophage targeting, reactive oxygen species (ROS) release and celastrol (CLT) encapsulation were achieved. The cytotoxicity, cellular uptake, internalization pathways and transmembrane transport efficiency of CS-PBE micelles were studied in Caco-2 and RAW264.7 cells. Hemolysis and organotoxicity tests were performed to assess the safety of the platform, while its therapeutic efficacy was investigated in high-fat diet-induced obese mice. Multifunctional micelles with macrophage targeting and ROS clearance capabilities were developed to improve the efficacy of CLT in treating obesity.studies indicated that CS-PBE micelles had better ability to target M1 macrophages, better protective effects on mitochondrial function, better ability to reduce the number of LPS-stimulated M1 macrophages, better ability to reduce the number of M2 macrophages, and better ability to scavenge ROS in inflammatory macrophages.studies have shown that CS-PBE micelles improve inflammation and significantly reduce toxicity of CLT in the treatment of obesity. In summary, CS-PBE micelles could significantly improve the ability to target inflammatory macrophages and scavenge ROS in adipose tissue to alleviate inflammation, suggesting that CS-PBE micelles are a highly promising approach for the treatment of obesity.
涉及脂肪巨噬细胞的炎症是肥胖的重要诱因。调节巨噬细胞极化,改善脂肪组织的炎症微环境是治疗肥胖的新策略。通过修饰硫酸软骨素的主链,得到了一种两亲性硫酸软骨素苯硼酸酯衍生物(CS-PBE)。利用 CS-PBE 自组装,实现了巨噬细胞靶向、活性氧(ROS)释放和雷公藤红素(CLT)包封。研究了 CS-PBE 胶束在 Caco-2 和 RAW264.7 细胞中的细胞毒性、细胞摄取、内化途径和跨膜转运效率。通过溶血和器官毒性试验评估了该平台的安全性,同时在高脂肪饮食诱导的肥胖小鼠中研究了其治疗效果。开发了具有巨噬细胞靶向和 ROS 清除能力的多功能胶束,以提高 CLT 治疗肥胖的疗效。研究表明,CS-PBE 胶束对 M1 巨噬细胞具有更好的靶向能力,对线粒体功能具有更好的保护作用,减少 LPS 刺激的 M1 巨噬细胞数量的能力更好,减少 M2 巨噬细胞数量的能力更好,清除炎症巨噬细胞中 ROS 的能力更好。研究表明,CS-PBE 胶束改善了炎症,显著降低了 CLT 治疗肥胖的毒性。总之,CS-PBE 胶束可以显著提高靶向炎症巨噬细胞和清除脂肪组织中 ROS 的能力,从而减轻炎症,表明 CS-PBE 胶束是治疗肥胖的一种很有前途的方法。